With the aim of accelerating Research and Development (R&D) dedicated to infectious diseases that have a strong impact on low-income countries, GSK has announced an investment of 1 billion pounds (approximately 1.16 billion euros) over 10 years . The new commitments are part of the British company’s goal of making a positive impact on the health of more than 2.5 billion people over the next decade. Research will focus on innovative drugs and vaccines to prevent and treat malaria, tuberculosis, HIV (through ViiV Healthcare), neglected tropical diseases and antimicrobial resistance (AMR), which continue to have a devastating impact among the most vulnerable and accounting for over 60% of the disease burden in many low-income countries. “I am delighted to renew our commitment to global health research for the next decade, consistent with our aim to combine our science and technology and talent to get ahead of the disease together and with our ambition to be a leader. impact on health, on a large scale – said Thomas Breuer, Chief Global Health Officer of GSK, speaking at the Kigali (Rwanda) summit on malaria and noncommunicable diseases (Ntd) – With our focus on scientific innovation in global health we have provided the first malaria vaccine (RTS, S) the first radical cure (tafenoquine) against malaria “Plasmodium” vivax as well as a new vaccine candidate against tuberculosis. We now have 31 new global R&D activities for health in 13 diseases impact to accelerate, and we must urgently work together to bring these potentially life-saving innovations to the people who need them. ” yes in reducing the impact of infectious diseases, including the elimination of lymphatic filariasis from Malawi – says the country’s health minister, Kumbize Kandodo Chiponda – But some diseases persist, because medicines and vaccines to prevent and treat them do not exist, or they became less effective due to increased resistance. The GSK announcement demonstrates the company’s commitment to bridging the innovation gap and is a fundamental step towards eliminating infectious diseases, which are a barrier to a healthier and more equitable world “. In detail – explains one notes – with the billion invested in R&D for global health, GSK will support: the supply of next-generation drugs for tuberculosis and malaria, offering shorter, simpler and safer treatment options for patients, including research and development of long-acting injectables to protect against Plasmodium falciparum malaria; through ViiV Healthcare, working in partnership with the goal of ending HIV / AIDS by developing and enabling access to innovative treatment and prevention for people living with HIV; reducing antibiotic resistance by advancing the industry-leading pipeline for vaccines, including first-in-class vaccines against non-typhoid salmonellosis (iNTS) and invasive shigellosis; catalyzing external funding for research and development on high-impact infectious diseases through collaborations and multi-sector alliances.To achieve these goals, GSK has formed a dedicated, non-commercial global health unit, for which success is measured only by impact on health. The model is designed to prioritize the prevention and treatment of infectious diseases in low-income countries where research can impact the health of millions of people, in pathological areas where there is little prospect of a commercial return on investment. . The unit includes global health innovation hubs dedicated to pharmaceuticals and vaccines that, in collaboration with world-class partners, work to accelerate the discovery and development of new drugs and vaccines. These hubs currently have 31 products in the R&D pipeline, including preclinical ones, destined for 13 high-impact infectious diseases. Kigali. The company reiterated its commitment to provide albendazole, already the largest drug donation ever, until lymphatic filariasis and soil-borne helminthiasis (Sth) morbidity are eliminated as public health concerns everywhere. GSK also confirmed that it is doubling the production of its adjuvant AS01 for use in the RTS vaccine, S against malaria, to help meet projected demand for the vaccine in the medium term. Over the next decade, this work will build on a commitment to long term and on the investments made by GSK in global health innovation. To date, this has produced significant new interventions including RTS, S, the first vaccine against malaria (and the first human vaccine against a parasite); tafenoquine, the first radical cure of malaria vivax, as well as a promising vaccine against tuberculosis, with development for low-income countries with a high TB burden, now led by the Bill and Melinda Gates Medical Research Institute.
Welcome! Log into your account
Recover your password
A password will be e-mailed to you.